Editorial
Pleasing serendipities that brings a little smile to our lips, such as the discovery of hydrostatics by Archimedes because of floating in a bath or the discovery of gravity by Sir Isaac Newton when an apple fell on his head when he was sleeping beneath a tree, have occurred several times in the history of science.
Similar serendipities have happened in medicine in the discovery of new drugs. That is why the late 19 th and the early 20 th centuries were known as "the age of serendipitous observations". Serendipity played an important role in the discovery of drugs such as penicillin, aspirin, sulfonamides and some other antibiotics. Beyond any doubt, the isolation of penicillin from the mould penicillium notatum by Alexander Fleming in 1928 is the best known one of such discoveries. The finding that the side effects of some drugs work as the treatment for another illness happened also due to serendipity. Among those, the most widely known cases are the discovery of sulfonamides as oral antidiabetic drugs, in the course of their use as antibacterial agents for the treatment of typhoid fever and the discovery of minoxidil's stimulant effect on hair growth while it was being investigated for its antihypertensive effects, resulting in its approval for use in the treatment of androgenic alopecia. As is the case for physical medicine, we can provide examples for serendipitous discovery of new drugs in psychopharmacology, such as the discovery of MAOIs based on the observation of antidepressant activity of iproniazid, originally intended to be used for the treatment of tuberculosis, and chlorpromazine that was discovered to have antipsychotic effects when it was originally developed for use as an anesthetic 1 . Despite the existence of several serendipitous drug discoveries in both general medicine and psychopharmacology, there have been plenty of frustrations too. We can come up with numerous examples of these frustrations such as nomifensine, a potent antidepressant, that was reported to cause severe immune hemolytic anemia a couple of years after its launch or nefazodone, another potent antidepressant with no sexual side effects and REM sleep disturbance, that was withdrawn from the market because of its severe hepatotoxicity or thioridazine, an antipsychotic with a successful history of more than 50 years that was stopped due to its serious prolongation of QTc interval or tianeptine that had the same end after its use in Europe and Turkey for almost a decade, because of hepatotoxicity and risk of abuse.
It is well known that antipsychotics in current use are successful in treating the positive symptoms of schizophrenia; however, there has been no agent developed that is effective on negative symptoms. It has been remarkably frustrating and disappointing to witness the withdrawal of a new drug because of adverse effects and/or lack of efficacy whereas the launch of a new drug brings great enthusiasm. Withdrawal or failure in launching of a new drug entity is not only a disappointment for patients and their families, who have been waiting hopefully, but also for healthcare providers like us. The most recent example of this is bitopertin* study. We were informed by Prof Daniel Umbricht, who had made remarkable contributions to the 4 th and the 5 th In other words, clozapine is effective in about half to 2/3 of treatment resistant patients. An antihypertensive/vasodilator agent, namely sodium nitroprusside** that has been in use for TR schizophrenia and its negative symptoms, should be mentioned. Among those studies, a placebo controlled clinical trial by Hallak et al. has reported that has for the first time demonstrated a safe, rapid (within hours), and long-lasting (several weeks) improvement of positive, negative, anxiety, and depressive symptoms in patients with schizophrenia after a single intravenous injection of sodium nitroprusside at a randomized, placebocontrolled trial 11 .This paper has provided a breathing space for clinicians, who have been feeling desperate in the field of schizophrenia. Though the small size of sampling of this study was a notable limitation, it would be a new potential and may expand horizons of the pharmacotherapy on schizophrenia. If confirmed by new studies, the findings of this scientific work could provide a novel initiative about the relationship between the observed NMDA receptor hypofunction and the n e g a t i v e a n d c o g n i t i v e s y m p t o m s o f schizophrenia 12 . In conclusion, although there are still numerous unmet needs and pending problems in the treatment of schizophrenia, it is hopeful to have ongoing phase II and phase III clinical trials (mostly phase II) on new drug entities exerting activity through the glutamatergic system or NO to have been proceeding quickly and accumulating data in a positive direction, to our knowledge 12 . We anticipate that the outcome of the ongoing studies in the field would please the patients, their families and healthcare providers. (NMDA and alpha-amino-3-hydroxy-5-methyl-4 
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* It is well known that the traditional models of s c h i z o p h r e n i a h a v e e m p h a s i z e d d o p a m i n e r g i
schizophrenia. The preclinical evidence has shown that it m i g h t b e p o s s i b l e t o d e v e l o p g l u t a m a t e -b a s e d antidepressants by not only modulating ionotropic
